227 related articles for article (PubMed ID: 25131876)
1. [Two cases of thymic carcinoid treated with octreotide long-acting repeatable].
Okabe N; Inoue T; Watanabe Y; Muto S; Hasegawa T; Ohsugi J; Higuchi M; Shio Y; Suzuki H
Gan To Kagaku Ryoho; 2014 Jul; 41(7):879-83. PubMed ID: 25131876
[TBL] [Abstract][Full Text] [Related]
2. Everolimus in combination with octreotide LAR in thymic atypical carcinoid.
Sakane T; Nakano T; Hagui E; Haneda H; Okuda K
Thorac Cancer; 2023 May; 14(15):1404-1407. PubMed ID: 37037489
[TBL] [Abstract][Full Text] [Related]
3. Thymic carcinoid responds to neoadjuvant therapy with sunitinib and octreotide: a case report.
Dham A; Truskinovsky AM; Dudek AZ
J Thorac Oncol; 2008 Jan; 3(1):94-7. PubMed ID: 18166847
[TBL] [Abstract][Full Text] [Related]
4. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.
Pavel ME; Hainsworth JD; Baudin E; Peeters M; Hörsch D; Winkler RE; Klimovsky J; Lebwohl D; Jehl V; Wolin EM; Öberg K; Van Cutsem E; Yao JC;
Lancet; 2011 Dec; 378(9808):2005-2012. PubMed ID: 22119496
[TBL] [Abstract][Full Text] [Related]
5. Comments on "Clinical value of monitoring plasma octreotide levels during chronic octreotide long-acting repeatable therapy in carcinoid patients".
Schran HF; Hager DF
Pancreas; 2008 Oct; 37(3):334-5; author reply 336-7. PubMed ID: 18815560
[No Abstract] [Full Text] [Related]
6. [A case of rectal carcinoid with multiple liver, lymph nodes and bone metastases that responded to an octreotide therapy].
Yamashita K; Takase S; Nakamura T; Matsuda Y; Imanishi T; Sumi Y; Suzuki S; Kamigaki T; Ku Y; Kuroda D
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2349-51. PubMed ID: 21224569
[TBL] [Abstract][Full Text] [Related]
7. Treatment of type I gastric neuroendocrine tumors with somatostatin analogs.
Khuroo MS; Khuroo MS; Khuroo NS
J Gastroenterol Hepatol; 2010 Mar; 25(3):548-54. PubMed ID: 20074162
[TBL] [Abstract][Full Text] [Related]
8. Metastatic thymic carcinoid responds to chemoradiation and octreotide: A case report.
Mei Z; Wang H; Ren S; Wei J; Gu Y
Medicine (Baltimore); 2018 Nov; 97(47):e13286. PubMed ID: 30461637
[TBL] [Abstract][Full Text] [Related]
9. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.
Wolin EM; Jarzab B; Eriksson B; Walter T; Toumpanakis C; Morse MA; Tomassetti P; Weber MM; Fogelman DR; Ramage J; Poon D; Gadbaw B; Li J; Pasieka JL; Mahamat A; Swahn F; Newell-Price J; Mansoor W; Öberg K
Drug Des Devel Ther; 2015; 9():5075-86. PubMed ID: 26366058
[TBL] [Abstract][Full Text] [Related]
10. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours.
Nilsson O; Kölby L; Wängberg B; Wigander A; Billig H; William-Olsson L; Fjälling M; Forssell-Aronsson E; Ahlman H
Br J Cancer; 1998 Feb; 77(4):632-7. PubMed ID: 9484822
[TBL] [Abstract][Full Text] [Related]
11. Five-year follow-up of patients treated for 1 year with octreotide long-acting release for enterochromaffin-like cell carcinoids.
Jianu CS; Fossmark R; Syversen U; Hauso Ø; Fykse V; Waldum HL
Scand J Gastroenterol; 2011 Apr; 46(4):456-63. PubMed ID: 21133821
[TBL] [Abstract][Full Text] [Related]
12. Carcinoid tumor of the thymus: a clinicopathologic report of two cases with a review of the literature.
Luh SP; Kuo C; Liu WS; Wu TC; Koo CL; Chen JY
Int Surg; 2005; 90(5):270-4. PubMed ID: 16625945
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and tolerability of long-acting octreotide in the treatment of thymic tumors: results of a pilot trial.
Longo F; De Filippis L; Zivi A; Vitolo D; Del Signore E; Gori B; Diso D; Anile M; Venuta F; De Giacomo T; Coloni CF
Am J Clin Oncol; 2012 Apr; 35(2):105-9. PubMed ID: 21325939
[TBL] [Abstract][Full Text] [Related]
14. [Successful treatment of carcinoid syndrome in two cases of bronchial carcinoid].
Katakami N; Matsumoto H; Ishihara K; Umeda B
Nihon Kyobu Shikkan Gakkai Zasshi; 1995 Nov; 33(11):1313-8. PubMed ID: 8583728
[TBL] [Abstract][Full Text] [Related]
15. Lung and Thymic Carcinoids.
Hann CL; Forde PM
Endocrinol Metab Clin North Am; 2018 Sep; 47(3):699-709. PubMed ID: 30098725
[TBL] [Abstract][Full Text] [Related]
16. Octreotide long-acting repeatable among elderly patients with neuroendocrine tumors: a survival analysis of SEER-Medicare data.
Shen C; Shih YC; Xu Y; Yao JC
Cancer Epidemiol Biomarkers Prev; 2015 Nov; 24(11):1656-65. PubMed ID: 26315553
[TBL] [Abstract][Full Text] [Related]
17. Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: a population-based analysis.
Shen C; Shih YC; Xu Y; Yao JC
Cancer; 2014 Jul; 120(13):2039-49. PubMed ID: 24676892
[TBL] [Abstract][Full Text] [Related]
18. Hepatic cytoreduction followed by a novel long-acting somatostatin analog: a paradigm for intractable neuroendocrine tumors metastatic to the liver.
Chung MH; Pisegna J; Spirt M; Giuliano AE; Ye W; Ramming KP; Bilchik AJ
Surgery; 2001 Dec; 130(6):954-62. PubMed ID: 11742323
[TBL] [Abstract][Full Text] [Related]
19. [Thymic carcinoid tumor--report of 3 operative cases].
Nakagawa K; Yasumitsu T; Kotake Y; Iwasaki T; In K
Nihon Kyobu Geka Gakkai Zasshi; 1992 Oct; 40(10):1955-61. PubMed ID: 1431419
[TBL] [Abstract][Full Text] [Related]
20. [Surgical treatment of recurrent thymic carcinoid--a case report].
Inoue M; Sato S; Sakagoshi N; Inoue T; Nagai I; Tanaka T
Nihon Kyobu Geka Gakkai Zasshi; 1994 Aug; 42(8):1188-92. PubMed ID: 7963834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
